Clinical Trials

Breast Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06312176 2026-04-02

MK-2870-010

Phase 3 Recruiting

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT05748834 2026-03-20

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 2 Recruiting

36 enrolled

Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2 Recruiting

30 enrolled

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04243616 2025-09-05

CemiHALT

36 enrolled

Invasive Breast Cancer

NCT05029999 2025-08-13

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Phase 1 Recruiting

30 enrolled

BreastGynecologicPlasma cellSarcoma

Breast Neoplasms

NCT05567601 2025-06-05

Doxil/Caelyx BE Study

Phase 1 Completed

36 enrolled

AIDS-related Kaposi sarcoma, Breast Neoplasms, Multiple Myeloma, Ovarian Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02488564 2025-02-03

met-HEReMYTA

49 enrolled

HER-2 Positive Breast Cancer

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

Phase 2 Recruiting

252 enrolled

Phase 2 Not yet recruiting

HER2-negative Breast Cancer

NCT06653972 2024-10-23

EASOVCWDITHABC

30 enrolled

Her2-negative Metastatic Breast Cancer

NCT03164993 2024-10-15

ALICE

68 enrolled

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT03409198 2024-10-15

ICON

82 enrolled

Breast Neoplasms, Neoplasms

NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1 Completed

35 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Phase 3 Recruiting

372 enrolled